Research Paper Volume 13, Issue 14 pp 19048—19063

Combined treatment with C16 peptide and angiopoietin-1 confers neuroprotection and reduces inflammation in 3-nitropropionic acid-induced dystonia mice

class="figure-viewer-img"

Figure 1. C16+Ang-1 treatment can alleviate 3-NP-induced motor functional impairment as shown by the open field (AB), pole-climbing (C), rotorod (D), and gripping ability (E) tests, and memory impairment in recognition as evidenced by the novel object recognition test (F). Measurements of the (A) total distance travelled by the mice and (B) mean velocity of the control, 3-NP, and 3-NP+C16+Ang-1 groups in the open field test. Motor functional assessment revealed neurological disabilities with 3-NP insult following 3-NP treatment, while the 3-NP+C16+Ang-1-treated mice showed a reversal of these effects. (C) Measurements of the mean pole climbing time for the three groups. (D) In the rotarod test, 3-NP-treated mice remained on the device for a significantly shorter time compared to control mice, but 3-NP+C16+Ang-1 treatment inhibited this phenomenon. (E) The average forepaw grip strength of 3-NP-treated mice decreased significantly compared with that of controls but improved with 3-NP+C16+Ang-1 treatment. (F) The discrimination scores (%) for the three groups showed that 3-NP impaired the object discovery ability of the mice while 3-NP+C16+Ang-1 treatment alleviated the disorder. aP < 0.05 versus control; bP < 0.05 versus 3-NP-treated mice.